Danaher Commits to Set Science-Based, Net-Zero Greenhouse Gas Emission Reduction Targets

Rhea-AI Summary

Danaher Corporation (NYSE: DHR) commits to science-based greenhouse gas emission reduction targets, aiming for net-zero value chain emissions by 2050. The company plans to reduce Scope 1 and 2 GHG emissions by 50.4% by 2032 compared to 2021, aligning with the Science Based Targets initiative (SBTi).

WASHINGTON, Feb. 22, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (Danaher) announced today it has committed to set science-based greenhouse gas (GHG) emission reduction targets in line with the Science Based Targets initiative (SBTi), including a long-term target to reach net-zero value chain emissions by no later than 2050. Danaher's pledge encompasses Scope 1, 2 and 3 GHG emissions and complements its existing commitment to reduce Scope 1 and 2 GHG emissions on an absolute basis by 50.4% by 2032 compared to 2021.

"At the heart of everything we do at Danaher is continuous improvement, and our sustainability program further exemplifies this commitment," said Rainer M. Blair, Danaher's President and Chief Executive Officer. "Committing to near- and long-term targets to achieve net-zero GHG emissions across our value chain is a critical step toward reducing our climate impact and builds on our long-term commitments to make a positive impact on human health."

Danaher will submit its GHG emission reduction targets to SBTi to be validated against the SBTi criteria. The SBTi is a partnership between CDP, the UN Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF) that defines and promotes best practice in science-based target setting, offers resources and guidance to reduce barriers to adoption, and independently assesses and approves companies' targets.

ABOUT DANAHER
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Our businesses partner closely with customers to solve many of the most important health challenges impacting patients around the world. Danaher's advanced science and technology - and proven ability to innovate - help enable faster, more accurate diagnoses and help reduce the time and cost needed to sustainably discover, develop and deliver life-changing therapies. Focused on scientific excellence, innovation and continuous improvement, our approximately 63,000 associates worldwide help ensure that Danaher is improving quality of life for billions of people today, while setting the foundation for a healthier, more sustainable tomorrow. Explore more at www.danaher.com.

FORWARD-LOOKING STATEMENTS
Statements in this release that are not strictly historical, including the statements regarding external validation of Danaher's targets, future reductions of GHG emissions and any other statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, potential future, adverse impacts on our business, results of operations and financial condition related to the COVID-19 pandemic, the impact of our debt obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, contractions or growth rates and cyclicality of markets we serve, competition, our ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully complete divestitures and other dispositions, our ability to integrate the businesses we acquire (including the acquisition of Abcam) and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, the rights of the United States government with respect to our production capacity in times of national emergency or with respect to intellectual property/production capacity developed using government funding, risks relating to product, service or software defects, product liability and recalls, risks relating to fluctuations in the cost and availability of the supplies we use (including commodities) and labor we need for our operations, our relationships with and the performance of our channel partners, uncertainties relating to collaboration arrangements with third-parties, the impact of deregulation on demand for our products and services, the impact of climate change, legal or regulatory measures to address climate change and our ability to address stakeholder expectations relating to climate change, labor matters and our ability to recruit, retain and motivate talented employees representing diverse backgrounds, experiences and skill sets, non-U.S. economic, political, legal, compliance, social and business factors (including the impact of military conflicts), disruptions relating to man-made and natural disasters, pension plan and healthcare costs, inflation and the impact of our By-law exclusive forum provisions. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2023 Annual Report on Form 10-K. These forward-looking statements speak only as of the date of this release and except to the extent required by applicable law, the Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

View original content:https://www.prnewswire.com/news-releases/danaher-commits-to-set-science-based-net-zero-greenhouse-gas-emission-reduction-targets-302069097.html

SOURCE Danaher Corporation

FAQ

What is Danaher Corporation's ticker symbol?

Danaher Corporation's ticker symbol is DHR.

What are Danaher Corporation's greenhouse gas emission reduction targets?

Danaher Corporation aims to achieve net-zero value chain emissions by 2050 and reduce Scope 1 and 2 GHG emissions by 50.4% by 2032 compared to 2021.

What is the Science Based Targets initiative (SBTi)?

The Science Based Targets initiative (SBTi) is a partnership promoting best practices in science-based target setting to reduce greenhouse gas emissions.

Who is Rainer M. Blair?

Rainer M. Blair is the President and Chief Executive Officer of Danaher Corporation.

What organizations are involved in the SBTi partnership?

The SBTi partnership includes CDP, the UN Global Compact, World Resources Institute (WRI), and the World Wide Fund for Nature (WWF).